Moderna (MRNA) Q2 2025 earnings

Modern On Friday, he decreased the highest end of the 2025 income appearance due to the delay in vaccine shipments to the UK, but he defeated Wall Street’s expectations for the second quarter while trying to reduce costs.

Moderna shares fell more than 9% on Friday.

The biotechnology company now expects full -year income to drop between $ 1.5 billion and $ 2.2 billion, at the top of this range. The results come one day after planning to reduce 10% of Moderna’s labor force, and the company contributed to a number of cost cuts while struggling with falling Covid vaccine sales and tried to launch more products.

In an interview, Modernna Chief Finance Manager Jamey Mock said that at the end of this year, instead of sending Spring Covid strengthens to the UK, the company would send these jabs to the country in the first quarter of 2026.

Mock, “deliveries from the end of the fiscal year, the first quarter of the next quarter to the end of the year, and to fulfill the supply for the spring booster in the UK.” He said.

Again on Friday, the company said that analysts lost less than they expected for the second quarter and recorded income exceeding the estimates.

Based on a questionnaire of LSEG’s analysts, what Moderna reported for the second quarter of Wall Street for the second quarter:

• Loss per share: $ 2.13 and $ 2.97 is an expected loss
• Revenues: 142 million dollars and 113 million dollars expected

Moderna released a second quarter of $ 142 million with a decrease of 41% of the previous year due to decreasing Covid vaccine sales. The majority of the second quarter income came from the Covid shot, which received $ 114 million for the period.

According to StreetCount estimates, this has exceeded $ 89 million that analysts expected for the period.

However, according to StreetCount estimates, the company said that respiratory synonymous virus vaccine is “negligible” sales compared to $ 5.9 million expected by analysts.

The company recorded 825 million dollars for the second quarter or $ 2.13 per share. This is compared with net damage to $ 1.3 billion or $ 3.33 per share reported compared to the previous year.

Mock said that Moderna’s efforts to reduce costs help the company to overcome estimates for the quarter. Authorized, the company’s second quarter operating expenses decreased from $ 1.6 billion to 27% in the same period of the previous year.

“If there is something really to read from the first half [of 2025] Perspective, from financial terms, on the cost side, Mok said Mock.